{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:35:54Z","timestamp":1769099754545,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mucopolysaccharidosis II (MPS II) is a rare lysosomal storage disease characterized by cognitive impairment in most patients. This post hoc analysis evaluated changes in cognitive function, adaptive behavior and functional outcomes in patients with neuronopathic MPS II over time. Fifty-five children with MPS II were enrolled in a 24-month observational study (NCT01822184). The Differential Ability Scales, second edition (DAS-II; early years battery for ages 2\u00a0years 6\u00a0months to 6\u00a0years 11\u00a0months, school age battery for ages 7\u00a0years to 17\u00a0years 11\u00a0months), Vineland Adaptive Behavior Scales, second edition (VABS-II) and the Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) were performed at baseline and 3-month intervals over 2\u00a0years. A subgroup of 38 children with a DAS-II General Conceptual Ability (GCA) score of 55\u201385 (below average\u2013very low abilities) at any time during the study were included in this analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean (standard deviation [SD]) early years DAS-II GCA score decreased from 73.4 (15.7, n\u2009=\u200922) at baseline to 62.7 (34.9, n\u2009=\u20096) at month 24. For the six patients with early years GCA assessments at baseline and month 24, mean (SD) GCA scores decreased from 72.3 (21.3) at baseline to 62.7 (34.9) at month 24. School age GCA scores were stable over 2\u00a0years: mean (SD) 72.4 (11.8, n\u2009=\u200910) at baseline; 74.3 (12.3, n\u2009=\u20098) at month 24. Mean (SD) VABS-II Adaptive Behavior Composite (ABC) scores were stable throughout the study (baseline, 81.8 [11.8, n\u2009=\u200936]; month 24, 81.0 [10.2, n\u2009=\u200913]). Some associations between items and domains of HS-FOCUS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and DAS-II GCA and VABS-II ABC scores were shown, but there was no clear pattern of changes in HS-FOCUS over 2\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The DAS-II measured changes in cognitive function over 2\u00a0years in younger patients with MPS II, whereas cognitive function in older patients remained stable. Further research is required to confirm the content validity of the DAS-II in different patient populations with MPS II. The VABS-II and HS-FOCUS were not sensitive tools for measuring behavioral and functional changes over 2\u00a0years. These findings may inform selection of appropriate cognitive and behavioral assessment tools for future studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-02118-3","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T10:02:29Z","timestamp":1638612149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Analysis of cognitive ability and adaptive behavior assessment tools used in an observational study of patients with mucopolysaccharidosis II"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6026-1435","authenticated-orcid":false,"given":"Karen S.","family":"Yee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Waisbren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"key":"2118_CR1","first-page":"3421","volume-title":"The metabolic and molecular bases of inherited disease","author":"E Neufeld","year":"2001","unstructured":"Neufeld E, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3421\u201352."},{"issue":"3","key":"2118_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267\u201377.","journal-title":"Eur J Pediatr"},{"issue":"7","key":"2118_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","volume":"10","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J, et al. Initial report from the Hunter Outcome Survey. Genet Med. 2008;10(7):508\u201316.","journal-title":"Genet Med"},{"key":"2118_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1750-1172-8-101","volume":"8","author":"M Raluy-Callado","year":"2013","unstructured":"Raluy-Callado M, Chen WH, Whiteman DA, Fang J, Wiklund I. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet J Rare Dis. 2013;8:101.","journal-title":"Orphanet J Rare Dis"},{"key":"2118_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ymgmr.2015.11.001","volume":"5","author":"CJ Hendriksz","year":"2015","unstructured":"Hendriksz CJ, Muenzer J, Vanderver A, Davis JM, Burton BK, Mendelsohn NJ, et al. Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment. Mol Genet Metab Rep. 2015;5:103\u20136.","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"2118_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","volume":"25","author":"ID Young","year":"1983","unstructured":"Young ID, Harper PS. The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983;25(4):481\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"2118_CR7","doi-asserted-by":"publisher","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","volume":"127","author":"JB Holt","year":"2011","unstructured":"Holt JB, Poe MD, Escolar ML. Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics. 2011;127(5):e1258\u201365.","journal-title":"Pediatrics"},{"key":"2118_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ymgmr.2016.03.005","volume":"7","author":"EG Shapiro","year":"2016","unstructured":"Shapiro EG, Rudser K, Ahmed A, Steiner RD, Delaney KA, Yund B, et al. A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II. Mol Genet Metab Rep. 2016;7:32\u20139.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"2118_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10897-013-9665-4","volume":"23","author":"M Needham","year":"2014","unstructured":"Needham M, Packman W, Rappoport M, Quinn N, Cordova M, Macias S, et al. MPS II: adaptive behavior of patients and impact on the family system. J Genet Couns. 2014;23(3):330\u20138.","journal-title":"J Genet Couns"},{"issue":"8","key":"2118_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465\u201373.","journal-title":"Genet Med"},{"issue":"2","key":"2118_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95\u2013101.","journal-title":"Genet Med"},{"issue":"1","key":"2118_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13023-017-0712-3","volume":"12","author":"J Muenzer","year":"2017","unstructured":"Muenzer J, Giugliani R, Scarpa M, Tylki-Szymanska A, Jego V, Beck M. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the Hunter Outcome Survey (HOS). Orphanet J Rare Dis. 2017;12(1):161.","journal-title":"Orphanet J Rare Dis"},{"key":"2118_CR13","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.2147\/DDDT.S139601","volume":"11","author":"DA Whiteman","year":"2017","unstructured":"Whiteman DA, Kimura A. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future. Drug Des Devel Ther. 2017;11:2467\u201380.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2118_CR14","doi-asserted-by":"publisher","first-page":"e30341","DOI":"10.1371\/journal.pone.0030341","volume":"7","author":"P Calias","year":"2012","unstructured":"Calias P, Papisov M, Pan J, Savioli N, Belov V, Huang Y, et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One. 2012;7(1):e30341.","journal-title":"PLoS One"},{"issue":"1","key":"2118_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/gim.2015.36","volume":"18","author":"J Muenzer","year":"2016","unstructured":"Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, et al. A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med. 2016;18(1):73\u201381.","journal-title":"Genet Med"},{"issue":"2","key":"2118_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2017.05.005","volume":"121","author":"D Janzen","year":"2017","unstructured":"Janzen D, Delaney KA, Shapiro EG. Cognitive and adaptive measurement endpoints for clinical trials in mucopolysaccharidoses types I, II, and III: a review of the literature. Mol Genet Metab. 2017;121(2):57\u201369.","journal-title":"Mol Genet Metab"},{"key":"2118_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgme.2017.09.007","volume":"122S","author":"EG Shapiro","year":"2017","unstructured":"Shapiro EG, Escolar ML, Delaney KA, Mitchell JJ. Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses. Mol Genet Metab. 2017;122S:8\u201316.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2118_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ymgme.2017.05.004","volume":"121","author":"JH van der Lee","year":"2017","unstructured":"van der Lee JH, Morton J, Adams HR, Clarke L, Ebbink BJ, Escolar ML, et al. Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: results of a consensus procedure. Mol Genet Metab. 2017;121(2):70\u20139.","journal-title":"Mol Genet Metab"},{"key":"2118_CR19","unstructured":"Elliott C. Differential Ability Scales: Introductory and technical handbook. 2nd ed. San Antonio, TX: Harcourt Assessment; 2007."},{"key":"2118_CR20","volume-title":"Vineland Adaptive Behavior Scales","author":"S Sparrow","year":"2005","unstructured":"Sparrow S, Cicchetti D, Balla D. Vineland Adaptive Behavior Scales. 2nd ed. Circle Pines, MN: American Guidance Service; 2005.","edition":"2"},{"issue":"9","key":"2118_CR21","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s11136-014-0703-y","volume":"23","author":"I Wiklund","year":"2014","unstructured":"Wiklund I, Raluy-Callado M, Chen WH, Muenzer J, Fang J, Whiteman D. The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: item reduction and further validation. Qual Life Res. 2014;23(9):2457\u201362.","journal-title":"Qual Life Res"},{"issue":"4","key":"2118_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s11136-012-0196-5","volume":"22","author":"I Wiklund","year":"2013","unstructured":"Wiklund I, Raluy-Callado M, Stull DE, Jangelind Y, Whiteman DA, Chen WH. The Hunter syndrome-functional outcomes for clinical understanding scale (HS-FOCUS) questionnaire: evaluation of measurement properties. Qual Life Res. 2013;22(4):875\u201384.","journal-title":"Qual Life Res"},{"issue":"1","key":"2118_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12955-018-1006-8","volume":"16","author":"M Mattera","year":"2018","unstructured":"Mattera M, Vernon MK, Raluy-Callado M, Mikl J. Validation of the shortened Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS). Health Qual Life Outcomes. 2018;16(1):209.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2118_CR24","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716\u201323.","journal-title":"IEEE Trans Autom Control"},{"issue":"1\u20132","key":"2118_CR25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2020.08.007","volume":"131","author":"JH van der Lee","year":"2020","unstructured":"van der Lee JH, Morton J, Adams HR, Clarke L, Eisengart JB, Escolar ML, et al. Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints. Mol Genet Metab. 2020;131(1\u20132):181\u201396.","journal-title":"Mol Genet Metab"},{"key":"2118_CR26","doi-asserted-by":"crossref","unstructured":"Kronenberger WG, Harrington M, Yee KS. Projected retained ability score (PRAS): a new methodology for quantifying absolute change in norm-based psychological test scores over time. Assessment. 2019:1073191119872250.","DOI":"10.1177\/1073191119872250"},{"key":"2118_CR27","unstructured":"FDA. Patient-focused drug development guidance public workshop. Methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments. Workshop date: October 15\u201316, 2018. Available from: https:\/\/www.fda.gov\/media\/116277\/download. Accessed 29 January 2021."},{"key":"2118_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ymgme.2017.09.010","volume":"122S","author":"ML Escolar","year":"2017","unstructured":"Escolar ML, Jones SA, Shapiro EG, Horovitz DDG, Lampe C, Amartino H. Practical management of behavioral problems in mucopolysaccharidoses disorders. Mol Genet Metab. 2017;122S:35\u201340.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2118_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ymgme.2016.04.006","volume":"118","author":"E Shapiro","year":"2016","unstructured":"Shapiro E, Bernstein J, Adams HR, Barbier AJ, Buracchio T, Como P, et al. Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. Mol Genet Metab. 2016;118(2):65\u20139.","journal-title":"Mol Genet Metab"},{"key":"2118_CR30","doi-asserted-by":"publisher","first-page":"100549","DOI":"10.1016\/j.ymgmr.2019.100549","volume":"22","author":"JB Eisengart","year":"2020","unstructured":"Eisengart JB, King KE, Shapiro EG, Whitley CB, Muenzer J. The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome. Mol Genet Metab Rep. 2020;22:100549.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02118-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02118-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02118-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T10:08:31Z","timestamp":1638612511000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02118-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02118-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained for all patients included in the study from their parent(s) or legally authorized guardian(s). All research performed was in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable; no individual patient details are included in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KSY and YW are full-time employees of Takeda Development Center Americas, Inc. and are stockowners of Takeda Pharmaceuticals Company Limited. MH was an employee of Shire, a member of the Takeda group of companies, when this research was performed, and is now an employee of Pfizer. SEW has received advisory board, consulting fees, research support and other remuneration from Shire, a member of the Takeda group of companies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"501"}}